각종 간질환에서 B 형 간염 바이러스 DNA polymerase 활성도와 HBeAg의 관계

DNA-Polymerase and HBeAg appear to be indicaters of relative infectivity of HBsAg-positive serum. The acute disease in the HBeAg-positive patients with acute hepatitis differed significantly from that of HBeAg-negative (HBsAg-positivie) patients. However it did not correlate with the type or severity of liver disease after HBV infection, since HBeAg was present in both chronic benign and chronic active hepatitis B infections. Presence of HBeAg was associated with increase in DNA polymerase activity and in number of circulating Dane particles in previous reports, but it does not correlate with DNA polymerase activity, Dane particles in our studies. To evaluate the activity of HBV DNA in various liver disease, we studed it in 20 patients with CAH, HCC, and 10 patients, who is carrier state with HBeAg, without HBeAg, AVH and CPH respectively. The mean value of HBV DNA polymerase activity is 4092.60+5429.36 cpm in HBe-positive heathy carriers, 203.80+52.80 cpm in HBe-negative healthy carriers, 386.30+471.58 cpm in CPH, 742.05+942. 77 cprn in VAH, 211.95+110.27 cpm in HCC, and 413.50+77.60 cpm in AVH. These results suggest that onging hepatitis B viral replication is more active in HBeAg positive healthy carriers than in carriers without HBeAg, a finding that may help explain the high prevalence of individuals. Thus, DNA polymerase appears to identify the period of peak hepatitis B virus replication, the result of antiviral agents therapy, and test will be useful in evaluating the safety and efficacy of future hepatitis B virus infection.